Jemperli (dostarlimab-gxly)

Effective Date: June 9, 2021  Number: MG.MM.PH.332

Medical Guideline Disclaimer
Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request for prior authorization. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes, and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary. If there is a discrepancy between this guideline and a member’s benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication. EmblemHealth Services Company LLC, (“EmblemHealth”) has adopted the herein policy in providing management, administrative and other services to, EmblemHealth Plan, Inc., EmblemHealth Insurance Company, EmblemHealth Services Company, LLC and Health Insurance Plan of Greater New York (HIP), ConnectiCare, Inc., ConnectiCare Insurance Company, Inc. ConnectiCare Benefits, Inc., and ConnectiCare of Massachusetts, Inc. related to health benefit plans offered by these entities. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

Definition
Jemperli (dostarlimab-gxly) is a programmed death receptor-1 (PD-1)-blocking IgG4 humanized monoclonal antibody. The binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T-cells inhibits T-cell proliferation and cytokine production. Since some tumors produce increased numbers of the PD-1 ligands, T-cell immune surveillance of tumors is also inhibited. Dostarlimab-gxly binds to the T-cell PD-1 receptor and blocks its interaction with the ligands. This block increased PD-1 activity resulting in decreased tumor growth.

Length of Authorization
Coverage will be provided for 1 year and may be renewed.

Dosing Limits [Medical Benefit]:
The recommended dosage is 500 mg every 3 weeks for 4 doses, followed by 1,000 mg every 6 weeks for dose 5 and beyond (administer dose 5 beginning 3 weeks after dose 4).

Guideline
I. INITIAL APPROVAL CRITERIA
Coverage will be provided when the following criteria are met:
Recurrent or advanced endometrial cancer

- Patient is 18 years of age or older; AND
- Jemperli is prescribed by, or in consultation with, an oncologist; AND
- Patient has diagnosis of recurrent or advanced endometrial cancer; AND
- Patient has disease that is mismatch repair deficient or microsatellite instability-high (MSI-H), as determined by an FDA-approved test; AND
- Disease has progressed on or following treatment with a platinum-containing regimen; AND
- The requested use is supported by FDA-approved prescribing information OR the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines (NCCN Guidelines®) and/or NCCN Drugs & Biologics Compendium (NCCN Compendium®) with a recommendation of category level 1 or 2A.

II. RENEWAL APPROVAL CRITERIA
Coverage can be renewed in 1-year intervals based on the following conditions:

- Stabilization of disease or absence of disease progression; AND
- Absence of unacceptable toxicity from the drug.

Applicable Procedure Codes

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>C9399</td>
<td>Unclassified drugs or biologicals</td>
</tr>
<tr>
<td>J9999</td>
<td>Not otherwise classified, antineoplastic drugs</td>
</tr>
</tbody>
</table>

Applicable NDCs

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>00173-0898-03</td>
<td>Jemperli 50mg/ml single dose, 10ml vial</td>
</tr>
</tbody>
</table>

Applicable Diagnosis Codes

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>C54.1</td>
<td>Malignant neoplasm of endometrium</td>
</tr>
</tbody>
</table>

Revision History

<table>
<thead>
<tr>
<th>Date</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>6/9/2021</td>
<td>New Policy</td>
</tr>
</tbody>
</table>

References